Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain.

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says the ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that damage brain ...

It's thought that this death is caused by Lewy bodies, which are abnormal clumps of protein that consist mostly of misfolded alpha-synuclein that travel between neurons. They can also cause Lewy ...

The PADOVA trial of alpha-synuclein-targeting antibody prasinezumab wasn't able to show a statistically significant extension in the time to motor progression in patients with early-stage ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

A drug that targets a build-up of proteins linked to Parkinson’s disease could slow the progression of motor symptoms in people with advanced forms of the condition. Although this shows promise ...

The major mechanism behind Parkinson’s disease is well established – a toxic form of a protein called alpha-synuclein that accumulates inside neurons in clusters, eventually driving cell death ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...